We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Antibodies against Complement Factor H Selectively Destroy Tumor Cells

By LabMedica International staff writers
Posted on 17 May 2016
Print article
Image: Molecular structure of factor H bound to C3b. In order to avoid self-attack, regulatory proteins such as factor H bind with C3b, a central component of the enzyme C3 convertase, to help the immune system recognize the body’s own tissue and keep complement in check (Photo courtesy of the University of Pennsylvania School of Medicine).
Image: Molecular structure of factor H bound to C3b. In order to avoid self-attack, regulatory proteins such as factor H bind with C3b, a central component of the enzyme C3 convertase, to help the immune system recognize the body’s own tissue and keep complement in check (Photo courtesy of the University of Pennsylvania School of Medicine).
Cancer researchers have identified and produced a monoclonal antibody that destroys tumor cells by blocking the activity of the protective protein complement factor H (CFH).

Investigators at Duke University (Durham, NC, USA) had reported previously an association between autoantibodies against complement factor H (CFH) and early-stage lung cancer. Patients with stage I NSCLC (non-small cell lung cancer) had a significantly higher incidence of anti-CFH antibody than those with late-stage NSCLC. This association led to the hypothesis that CFH antibodies that arise in lung cancer patients may promote anti-tumor cell activity and that CFH antibody administration might provide a unique way to stimulate a long-term immune response and treat cancer.

CFH prevents complement-mediated cytotoxicity (CDC) by inhibiting formation of cell-lytic membrane attack complexes on self-surfaces. CHF is a member of the regulators of complement activation family and is a complement control protein. It is a large (155 kilodaltons), soluble glycoprotein that circulates in human plasma (at typical concentrations of 200–300 micrograms per milliliter). Its principal function is to regulate the Alternative Pathway of the complement system, ensuring that the complement system is directed towards pathogens or other dangerous material and does not damage host tissue.

In the current study the investigators isolated and expressed DNA sequences encoding high-affinity human CFH antibodies directly from single, sorted B-cells obtained from patients with the antibody.

They reported in the May 5, 2016, online edition of the journal Cell Reports that the co-crystal structure of a CFH antibody-target complex showed a conformational change in the target relative to the native structure. This recombinant CFH antibody caused complement activation and release of anaphylatoxins, killed tumor cells in vitro, and inhibited tumor growth in vivo.

"This is the first completely human-derived antibody developed as an anti-cancer therapy, which is very different from other immunotherapy approaches," said senior author Dr. Edward F. Patz, Jr., professor of pharmacology and cancer biology at Duke University. "This could represent a whole new approach to treating cancer, and it is exciting because the antibody selectively kills tumor cells, so we do not have significant side effects to achieve tumor control. We believe we can modulate the immune response and let the body's own immune system take over to either kill the tumor or keep it from growing."

Related Links:
Duke University

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Reagent Reservoirs
Reagent Reservoirs

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.